Synergistic effects of AgNPs and zileuton on PCOS via ferroptosis and inflammation mitigation

• Published in: Redox report : communications in free radical research 2025-12, Vol.30 (1), p.2445398
• Main Authors: Eltokhy, Amira K, El-Shaer, Rehab Ahmed Ahmed, El-Deeb, Omnia Safwat, Farghal, Eman E, Ibrahim, Rowida Raafat, Elesawy, Rasha, Awad, Marwa Mahmoud, Ismail, Radwa, Motawea, Shaimaa M, Shatat, Doaa, Hafez, Yasser Mostafa, El Hanafy, Hend Ahmed, Atef, Marwa Mohamed
• Format: Article
• Language: English
• Subjects: AgNPs; Animals; Antioxidants - pharmacology; COX-2; Female; Ferroptosis; Ferroptosis - drug effects; Hydroxyurea - analogs & derivatives; Hydroxyurea - pharmacology; Inflammation - drug therapy; Inflammation - metabolism; Metal Nanoparticles - therapeutic use; Panx1; Polycystic Ovary Syndrome - drug therapy; Polycystic Ovary Syndrome - metabolism; Rats; Silver; TLR4; VEGF
• ISSN: 1743-2928; 1351-0002; 1743-2928
• DOI: 10.1080/13510002.2024.2445398

The most prevalent endocrine disorder affecting women is PCOS. Programmed death of ovarian cells has yet to be elucidated. Ferroptosis is a kind of iron-dependent necrosis featured by significantly Fe -dependent lipid peroxidation. The ongoing study aimed to reinforce fertility by combining therapy with AgNPs and (Zileuton) in PCOS rats' model. The study included 75 adult female rats divided into 5 groups; control, PCOS, PCOS treated with AgNPs, PCOS treated with Zileuton, and PCOS group treated with AgNPs and Zileuton. The study investigated the anti-ferroptotic, anti-inflammatory, antioxidant, antiapoptotic, histopathological and immunohistochemical examinations of COX-2 and VEGF. The combination of AgNPs and Zileuton showed significant reduction of inflammatory mediators (IL-6, TNF-α, NFk-B) compared with diseased group ( -